Receive our newsletter – data, insights and analysis delivered to you
  1. Dashboards
November 5, 2021

BD reports 7.3% increase in Q4 2021 revenues

The company launched the BD COR System and BD FACSymphony A1 Cell Analyzer during the quarter.

Becton, Dickinson and Company (BD) has reported revenues of $5.1bn, representing a 7.3% increase for the fourth quarter (Q4) of 2021 compared to $4.7bn in the prior-year quarter.

For the full fiscal year 2021, the company reported $20.2bn in revenues, an 18.3% increase, on a reported basis, as against $17.1bn last year.

BD’s Medical business unit reported $2.53bn in revenue, a 9.2% increase from $2.32bn reported in the same quarter last year, while the revenues from the company’s Life Sciences segment increased by 2.9% to $1.53bn during the period.

Revenues in the Interventional segment stood at $1.07bn, an increase of 9.5% from $978m reported last year.

Additionally, BD repurchased three million shares for a total consideration of $750m during Q4.

Recently, the company has also launched products that include the BD COR System and BD FACSymphony A1 Cell Analyzer.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

The company received emergency use authorization (EUA) for the BD Veritor At-Home COVID-19 Test from the US Food and Drug Administration (FDA) as well as 510(k) clearance for the Rotarex Rotational Excisional Atherectomy System.

BD chairman, CEO and president Tom Polen said: “Our strong performance in fiscal 2021 was driven by the extraordinary efforts of our global team and demonstrates the resilience of BD’s portfolio in even the most uncertain health care environments.

“We also took a number of critical steps this year to lay the foundation for the next phase of our growth, which included strengthening our balance sheet and cash flows, increasing our investments into higher-growth spaces, and stepping up our pace of tuck-in M&A activity.”

Next year, the company hopes to generate $19.3bn to $19.5bn in revenues.

Last month, BD and the US Biomedical Advanced Research and Development Authority collaborated for the development of a range of combination diagnostic tests for Covid-19.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU